Shire’s Fosrenol User Fee Date Is Oct. 26 Following 90-Day Extension
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends the review timeline to evaluate recently submitted dosage strength and formulation data. Shire says no clinical or safety concerns have been raised and market preparation for a late 2004 launch is proceeding as planned.
You may also be interested in...
Shire's Fosrenol Marketing Campaign Will Follow Adderall Model
Detailing efforts for the end-stage renal disease therapy will focus on the top-prescribing nephrologists and dieticians, Shire CEO Emmens says. Company will highlight Fosrenol's high selectivity and potency to differentiate the product from Genzyme's Renagel.
Shire's Fosrenol Marketing Campaign Will Follow Adderall Model
Detailing efforts for the end-stage renal disease therapy will focus on the top-prescribing nephrologists and dieticians, Shire CEO Emmens says. Company will highlight Fosrenol's high selectivity and potency to differentiate the product from Genzyme's Renagel.
Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End
Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.